New eczema drug enters first human trials

NCT ID NCT07527923

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is the first time REGN20423 is being tested in humans. It will enroll 144 adults, first healthy volunteers and then people with atopic dermatitis (eczema). The goal is to check safety, side effects, how the drug moves through the body, and whether it helps eczema symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: REGN20423 (an experimental drug)
What this could lead to: If successful, this could lead to a new treatment option for atopic dermatitis (eczema) that helps control symptoms.
What could go wrong: This is a very early Phase 1 trial, so the drug may not prove safe or effective. It has never been tested in humans before, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema dermatitis Eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS HEALTHY VOLUNTEER

Contacts and locations

Locations

Center for Clinical Pharmacology University Hospitals Leuven (UZ Leuven)
RECRUITING

Leuven, Vlaams-Brabant, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.